Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
FATE
Home
/
FATE

NASDAQ
$2.09
$2.09

Overview

Price performance
Low
$2.02
High
$2.10
After hours. Last updated: Nov 4, 2026, 9:00 PM UTC
$
2.09
0.05 (2.45%)
Average, 50 days
$2.27
$1.97
Open
$2.07
Previous close
$2.04
52-week high
$3.23
Jul 13, 2026 (4 months ago)
52-week low
$0.95
Nov 14, 2025 (1 year ago)
120.00%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
243.61M
Volume
723 991
Total Return (3M)
-18.68%
Total Return (1Y)
75.63%
—
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
Website
fatetherapeutics.com
About
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.

Frequently asked questions

FATE · Fate Therapeutics, Inc.

01What is Fate Therapeutics, Inc. stock price today?

The current price of FATE is $2.09 — it has increased by 2.45% since the previous close. Data as of Nov 4, 2026.

02Is Fate Therapeutics, Inc. stock price growing?

FATE is down 1.88% over the past week, down 9.91% over the past month and up 75.63% over the past year. The price is above its 200-day moving average of $1.97.

03What is Fate Therapeutics, Inc. market cap?

Fate Therapeutics, Inc. has a market capitalization of $243.61M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

04Does Fate Therapeutics, Inc. pay dividends?

Fate Therapeutics, Inc. has not paid any dividends over the past year.

05How volatile is FATE stock?

In the latest trading session FATE moved between $2.03 and $2.10, a range of 3.59% of its current price.

06What are FATE stock 52-week high and low?

Over the past 52 weeks FATE has traded between $0.95 and $3.23. The current price is 35.29% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.